{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:29:58Z","timestamp":1770424198864,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,7]]},"DOI":"10.7759\/cureus.66408","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:37:26Z","timestamp":1723088246000},"source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis Masked by Urinary Tract Infection"],"prefix":"10.7759","author":[{"given":"Sukhjinder","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikechukwu R","family":"Ogbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin Roy P","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre E","family":"Manov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2022.11.002","article-title":"Prescribing trends of the sodium-glucose cotransporter-2 inhibitors among different physician specialties in Canada (2015-2021)","volume":"47","author":"Alkabbani W","year":"2023","unstructured":"Alkabbani W, Gamble JM. Prescribing trends of the sodium-glucose cotransporter-2 inhibitors among different physician specialties in Canada (2015-2021). Can J Diabetes. 2023, 47:153-61. 10.1016\/j.jcjd.2022.11.002","journal-title":"Can J Diabetes"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0081","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla P","year":"2017","unstructured":"Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017, 2017:10.1530\/EDM-17-0081","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019-0284","article-title":"Diabetic ketoacidosis: update on management","volume":"19","author":"Evans K","year":"2019","unstructured":"Evans K. Diabetic ketoacidosis: update on management. Clin Med (Lond). 2019, 19:396-8. 10.7861\/clinmed.2019-0284","journal-title":"Clin Med (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa P","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021, 12:514-23. 10.4239\/wjd.v12.i5.514","journal-title":"World J Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update","volume":"29","author":"Nespoux J","year":"2020","unstructured":"Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020, 29:190-8. 10.1097\/MNH.0000000000000584","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S212003","article-title":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician\u2019s guide","volume":"12","author":"Simes BC","year":"2019","unstructured":"Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician\u2019s guide. Diabetes Metab Syndr Obes. 2019, 12:2125-36. 10.2147\/DMSO.S212003","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen I","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015, 38:420-8. 10.2337\/dc14-1096","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey CJ","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022, 22:39-52. 10.1007\/s11892-021-01442-z","journal-title":"Curr Diab Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta S","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022, 11:927-40. 10.4103\/jfmpc.jfmpc_644_21","journal-title":"J Family Med Prim Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33892","article-title":"Empagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus","volume":"15","author":"Chauhan S","year":"2023","unstructured":"Chauhan S, Manov A, Dhillon GS, Shah P. Empagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus. Cureus. 2023, 15:e33892. 10.7759\/cureus.33892","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1506573","article-title":"Type 2 diabetes, SGLT2 inhibitors, and glucose secretion","volume":"373","author":"Hattersley AT","year":"2015","unstructured":"Hattersley AT, Thorens B. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med. 2015, 373:974-6. 10.1056\/NEJMcibr1506573","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4384","article-title":"Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature","volume":"11","author":"Gajjar K","year":"2019","unstructured":"Gajjar K, Luthra P. Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature. Cureus. 2019, 11:e4384. 10.7759\/cureus.4384","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg RM","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-2664.e1. 10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"ref15","article-title":"Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes","volume":"40","author":"Ndefo UA","year":"2015","unstructured":"Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015, 40:364-8.","journal-title":"P T"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245896-empagliflozin-associated-euglycemic-diabetic-ketoacidosis-masked-by-urinary-tract-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:37:30Z","timestamp":1723088250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245896-empagliflozin-associated-euglycemic-diabetic-ketoacidosis-masked-by-urinary-tract-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.66408","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,7]]}}}